Page 18 - Anemia Hemolitica No autoinmune

12
tary spherocytosis, carried out on a large number of than that recently reported by Crisp et al., and similar to
Table 2. (A) Sensitivity of single tests in patients with hereditary spherocytosis (HS) grouped according to the biochemical defect. (B) The sensi- tivity of combined tests in total HS cases. The number represents the ratio of positive cases/total cases with percent values in brackets.
A
Total HS patients
HS with biochemical defect Spectrin
Band 3
Combined spectrin/ankyrin
HS with undetectable defect
B
EMA-binding GLT
AGLT
143/150 (95%)
135/141 (96%) 70/73 (96%) 56/59 (93%)
9/9 (100%)
8/9 (88%)
Pink
136/150 (91%)
131/141 (93%) 67/73 (92%) 55/59 (93%)
9/9 (100%)
2/9 (22%)
OF (NaCl fresh)
102/150 (68%)
100/141 (71%) 51/73 (70%) 43/59 (73%)
6/9 (67%)
3/9 (33%)
EMA + Pink
149/150 (99%)
OF (NaCl inc.)
122/150 (81%)
119/141 (84%) 62/73 (85%) 49/59 (83%)
8/9 (89%)
4/9 (44%)
OF (NaCl inc.) + AGLT
146/150 (97%)
7% 140/150 (93%) 31%92/150
(61%)
(64%) (61%) (64%) (78%)
(22%)
132/141 (94%) 68/73 (93%)
90/141 45/73 38/59 7/9
2/9
55/59
9/9
8/9
(93%)
(100%)
(88%)
Total HS patients 150/150 (100%)
OF: osmotic fragility; Inc.: incubated.
100 90
Todos fueron positivos en al menos dos pruebas.
Splenectomized
EMA + AGLT
EMA + OF (NaCl fresh)
143/150 (95%)
EMA + OF (NaCl inc.)
143/150 (95%)